Nasdaq:FLGT
Fulgent Genetics, Inc.
A genetic diagnostics leader providing rare disease solutions and oncology analytics with a recovering 2025 revenue of $322.7M against a net loss of $61.6M.
Key Metrics
Investment Thesis
Bull Case
The company has demonstrated resilience with revenue growth in 2025 and maintains a substantial cash balance of $50.3M alongside significant marketable security proceeds, providing runway for R&D. Strategic positioning in the rare disease space offers high barriers to entry and potential for margin expansion as testing volumes stabilize.
Bear Case
The company is burning through cash with operating losses widening to $-61.6M in 2025 after a significant drop from 2022 profits, raising concerns about solvency given the $530M retained earnings deficit. The sharp revenue decline from 2022's $619M peak and continued negative free cash flow indicate fundamental business model challenges that may persist.
About Fulgent Genetics, Inc.
Fulgent Genetics is a diagnostic laboratory specializing in genetic testing and data analytics for rare disease diagnosis, oncology, and reproductive medicine. Serving markets across the United States and internationally, the company leverages its proprietary DNA sequencing technologies to provide actionable insights for patients and physicians. Key revenue streams include genomic testing services, software subscriptions, and partnerships with healthcare providers and pharmaceutical companies.
Analysis
Management Discussion
Despite a partial revenue recovery in 2025 to $322.7M compared to the prior year's $283.5M, the company continues to post substantial net losses of $61.6M, with operating profit remaining negative at $-91.1M. Cash flow from operations turned significantly negative at $-101.6M, suggesting heavy burn rates that are not yet offset by non-cash adjustments like share-based compensation or depreciation.
Industry Overview
The genetic diagnostics industry is experiencing rapid growth driven by advances in sequencing technology and increasing demand for personalized medicine, yet it faces intense competition and high regulatory hurdles. Companies must balance heavy investment in R&D with the need to achieve profitability in a capital-intensive sector.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $619.0M | $289.2M | $283.5M | $322.7M |
| Cost of Revenue | $252.1M | $184.8M | $176.3M | $191.8M |
| Gross Profit | $366.9M | $104.5M | $107.2M | $130.9M |
| Operating Expenses | $188.4M | $300.0M | $181.1M | $222.0M |
| Operating Income | $178.5M | $-195.5M | $-73.9M | $-91.1M |
| R&D | $28.9M | $41.4M | $48.8M | $53.9M |
| G&A | $111.1M | $89.0M | $88.1M | $116.7M |
| Marketing | $38.9M | $41.5M | $36.2M | $43.4M |
| Stock-Based Comp | $32.6M | $42.9M | $44.5M | $39.6M |
| D&A | $32.7M | $26.1M | $24.9M | $24.1M |
| Depreciation | $25.5M | $17.5M | $16.4M | $15.7M |
| Amortization | $6.5M | $7.8M | $8.0M | $8.0M |
| Other OpEx | $9.5M | $128.1M | $8.0M | $8.0M |
| Non-Operating Income | $5.5M | $21.4M | $22.0M | $21.1M |
| Interest Expense | $346.0K | — | — | — |
| Interest Income | — | — | $31.3M | $30.9M |
| Pre-Tax Income | $184.0M | $-174.1M | $-52.0M | $-70.0M |
| Income Tax | $42.1M | $1.2M | $-8.1M | $-8.4M |
| Continuing Ops | $141.9M | $-175.2M | $-43.8M | $-61.6M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $141.9M | $-175.2M | $-43.8M | $-61.6M |
| Minority Interest | $-1.5M | $-7.4M | $-1.1M | $-1.1M |
| Net to Common | $143.4M | $-167.8M | $-42.7M | $-60.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $627.9M | $507.8M | $353.6M | $550.5M |
| Cash & Equivalents | $79.5M | $97.5M | $55.1M | $50.2M |
| Accounts Receivable | $52.7M | $51.1M | $69.0M | $84.8M |
| Other Current Assets | $495.6M | $359.2M | $229.4M | $415.5M |
| Long-Term Assets | $758.2M | $727.5M | $866.4M | $663.0M |
| PP&E (Net) | $81.4M | $83.5M | $105.5M | $112.5M |
| Intangibles | $150.6M | $143.1M | $135.0M | $133.3M |
| Goodwill | $143.0M | $22.1M | $22.1M | $25.1M |
| Operating Leases | $14.8M | $10.8M | $5.4M | $5.0M |
| Other LT Assets | $368.4M | $468.1M | $598.4M | $387.2M |
| Total Assets | $1.39B | $1.24B | $1.22B | $1.21B |
| Current Liabilities | $88.1M | $73.0M | $72.9M | $85.0M |
| Accounts Payable | $23.1M | $15.4M | $18.4M | $18.7M |
| Current Leases | $6.1M | $4.0M | $1.4M | $1.5M |
| Deferred Revenue | $3.2M | $2.9M | $2.2M | $3.6M |
| Other Current Liab | $30.7M | $20.1M | $26.6M | $27.2M |
| Long-Term Liabilities | $28.1M | $29.0M | $17.9M | $21.8M |
| LT Operating Leases | $8.8M | $7.1M | $4.1M | $3.8M |
| Other LT Liab | $19.3M | $21.9M | $13.8M | $18.1M |
| Total Liabilities | $116.2M | $102.0M | $90.8M | $106.8M |
| Shareholders' Equity | $1.27B | $1.13B | $1.13B | $1.11B |
| Retained Earnings | $801.0M | $633.2M | $590.5M | $530.0M |
| AOCI | $-20.9M | $1.2M | $-368.0K | $7.5M |
| Total L&E | $1.39B | $1.24B | $1.22B | $1.21B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $141.9M | $-175.2M | $-43.8M | $-61.6M |
| Non-Cash Adjustments | $233.4M | $196.7M | $44.8M | $33.2M |
| Working Capital Changes | $-121.8M | $5.5M | $20.1M | $-73.2M |
| Cash from Operations | $253.5M | $27.0M | $21.1M | $-101.6M |
| Capital Expenditures | $18.8M | $22.2M | $40.3M | $22.6M |
| Cash from Investing | $-261.3M | $38.9M | $-58.4M | $111.4M |
| Share Buybacks | $74.3M | $25.1M | $225.0K | $10.9M |
| Cash from Financing | $-77.1M | $-47.8M | $-4.8M | $-14.8M |
| FX Effect | $-453.0K | $-149.0K | $-55.0K | $105.0K |
| Net Change in Cash | $-85.4M | $18.0M | $-42.2M | $-5.0M |
| Beginning Cash | $164.9M | $79.5M | $97.5M | $55.3M |
| Ending Cash | $79.5M | $97.5M | $55.3M | $50.3M |
Frequently Asked Questions
How does Fulgent Genetics, Inc. make money?
Genomic testing services for rare diseases, oncology molecular diagnostics, reproductive medicine testing, and digital health software/analytics platforms.
What are the main risks for FLGT?
Persistent operating losses and deepening retained earnings deficit indicating ongoing financial distress, significant revenue contraction from 2022 levels suggesting market or operational headwinds, high R&D and marketing expenses eroding profitability, and potential regulatory scrutiny on genetic data privacy.
What is FLGT's competitive advantage?
Proprietary high-throughput DNA sequencing technology enabling rapid and accurate rare disease diagnosis, a robust proprietary database of genetic variants, and strong partnerships with major healthcare systems and pharmaceutical firms.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.